A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin's lymphoma: investigation of the current protocol through theoretical modelling results.
Doxorubicin treatment outcomes for non-Hodgkin's lymphomas (NHL) are mathematically modelled and computationally analyzed. The NHL model includes a tumor structure incorporating mature and immature vessels, vascular structural adaptation and NHL cell-cycle kinetics in addition to Doxorubicin pharmacokinetics (PK) and pharmacodynamics (PD). Simulations provide qualitative estimations of the effect of Doxorubicin on high-grade (HG), intermediate-grade (IG) and low-grade (LG) NHL. Simulation results imply that if the interval between successive drug applications is prolonged beyond a certain point, treatment will be inefficient due to effects caused by heterogeneous blood flow in the system.
Ribba
B
B
Institute for Medical BioMathematics, 10 Hate'ena Street, P.O.B. 282, 60991 Bene Ataroth, Israel.
Marron
K
K
Agur
Z
Z
Alarcón
T
T
Maini
P K
PK
D002453:Cell Cycle / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003198:Computer Simulation; D004317:Doxorubicin / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007700:Kinetics; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008962:Models, Theoretical; D012039:Regional Blood Flow / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome
D004317:Doxorubicin